Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

被引:288
作者
Holst, Frederik
Stahl, Phillip R.
Ruiz, Christian
Hellwinkel, Olaf
Jehan, Zeenath
Wendland, Marc
Lebeau, Annette
Terracciano, Luigi
Al-Kuraya, Khawla
Jaenicke, Fritz
Sauter, Guido
Simon, Ronald [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, D-20246 Hamburg, Germany
[2] Univ Basel Hosp, Dept Pathol, CH-4031 Basel, Switzerland
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, D-20246 Hamburg, Germany
[5] King Faisal Specialist Hosp & Res Ctr, Riyadh 21211, Saudi Arabia
关键词
D O I
10.1038/ng2006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Using an Affymetrix 10K SNP array to screen for gene copy number changes in breast cancer, we detected a single-gene amplification of the ESR1 gene, which encodes estrogen receptor alpha, at 6q25. A subsequent tissue microarray analysis of more than 2,000 clinical breast cancer samples showed ESR1 amplification in 20.6% of breast cancers. Ninety-nine percent of tumors with ESR1 amplification showed estrogen receptor protein overexpression, compared with 66.6% cancers without ESR1 amplification ( P < 0.0001). In 175 women who had received adjuvant tamoxifen monotherapy, survival was significantly longer for women with cancer with ESR1 amplification than for women with estrogen receptor - expressing cancers without ESR1 amplification ( P = 0.023). Notably, we also found ESR1 amplification in benign and precancerous breast diseases, suggesting that ESR1 amplification may be a common mechanism in proliferative breast disease and a very early genetic alteration in a large subset of breast cancers.
引用
收藏
页码:655 / 660
页数:6
相关论文
共 26 条
[11]  
Koivisto P, 1997, CANCER RES, V57, P314
[12]  
Nessling M, 2005, CANCER RES, V65, P439
[13]  
Pauletti G, 1996, ONCOGENE, V13, P63
[14]   Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment [J].
Pegram, MD ;
Lipton, A ;
Hayes, DF ;
Weber, BL ;
Baselga, JM ;
Tripathy, D ;
Baly, D ;
Baughman, SA ;
Twaddell, T ;
Glaspy, JA ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2659-2671
[15]   Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials [J].
Press, MF ;
Sauter, G ;
Bernstein, L ;
Villalobos, IE ;
Mirlacher, M ;
Zhou, JY ;
Wardeh, R ;
Li, YT ;
Guzman, R ;
Ma, YL ;
Sullivan-Halley, J ;
Santiago, A ;
Park, JM ;
Riva, A ;
Slamon, DJ .
CLINICAL CANCER RESEARCH, 2005, 11 (18) :6598-6607
[16]  
Rose C, 1980, Recent Results Cancer Res, V71, P134
[17]   Tissue microarrays for comparing molecular features with proliferation activity in breast cancer [J].
Ruiz, C ;
Seibt, S ;
Al Kuraya, K ;
Siraj, AK ;
Mirlacher, M ;
Schraml, P ;
Maurer, R ;
Spichtin, H ;
Torhorst, J ;
Popovska, S ;
Simon, R ;
Sauter, G .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) :2190-2194
[18]  
SAUTER G, 1993, CANCER RES, V53, P2199
[19]   HETEROGENEITY OF CHROMOSOME-17 AND ERBB-2 GENE COPY NUMBER IN PRIMARY AND METASTATIC BLADDER-CANCER [J].
SAUTER, G ;
MOCH, H ;
GASSER, TC ;
MIHATSCH, MJ ;
WALDMAN, FM .
CYTOMETRY, 1995, 21 (01) :40-46
[20]  
Shoker BS, 1999, J PATHOL, V188, P237